You can buy Lucimird at the lowest price at Nextgen.ooo online pharmacy. Mirdametinib is a mitogen-activated protein kinase (MAP2K, MEK, MAPKK) inhibitor. On February 11, 2025, mirdametinib was approved by the FDA for the treatment of neurofibromatosis type 1 (NF1). NF1 is an autosomal-dominant genetic condition caused by loss-of-function variants in the NF1 tumour suppressor gene, leading to neurofibromin dysfunction and aberrant activation of the mitogen-activated protein kinase (MAPK) pathway. Mirdametinib selectively and potently inhibits the MEK1/2 enzymes.
 
NF1 is caused by the loss-of-function variants in the NF1 tumour suppressor gene, which encodes neurofibromin: Neurofibromin loss in tumour cells leads to dysregulated Ras signalling with hyperactivation of downstream Ras effectors, including mitogen-activated protein kinase (MAPK, MEK) and its downstream effector extracellular signal–regulated protein kinase (ERK). As the MAPK pathway regulates cellular functions such as cellular growth and senescence, dysregulation of this pathway aberrant glioblastoma cell growth. Mirdametinib is a highly selective, non-competitive inhibitor of MEK1/2. In vitro, mirdametinib inhibited kinase activity of MEK1 and MEK2 and downstream phosphorylation of ERK.